Various C-glucopyranosyl-1,2,4-triazolones were designed as potential inhibitors of glycogen phosphorylase. Syntheses of these compounds were performed with O-perbenzoylated glucose derivatives as precursors. High temperature ring closure of
Introduction
Glycogen phosphorylase (GP) inhibitors (GPIs) may find applications in antidiabetic therapy especially in type 2 diabetes mellitus, 1 but also in other diseases like cerebral 2, 3 and cardiac 4 ischemias, other cardiovascular impairments, 4, 5 and tumours. 6, 7 A very broad range of compounds with a number of scaffolds was shown to have inhibitory effect against GP 8 through binding to one (or sometimes more) of the binding sites discovered so far. 9 The catalytic site of GP can be targeted by glucose derivatives which are competitive inhibitors of the enzyme. 10, 11 Several glucose based GPIs show submicromolar efficiency: the best known inhibitors can be found among glucopyranosylidene-spiro-heterocycles, N-acyl-N'-β-Dglucopyranosyl ureas, and C-β-D-glucopyranosyl heterocycles. In the latter class of compounds structure-activity relationships have been established for 5-membered heterorings and some of their benzologs (Chart 1). Thus, 2-β-D-glucopyranosyl benzothiazole 1 proved to be a weaker inhibitor in comparison to benzimidazole 2. 12 This observation could be rationalized by X-ray crystallography of the enzymeinhibitor complexes showing an H-bond between the imidazole NH and the main chain carbonyl of His377 in the vicinity of the active site of GP. 13 Extension of 2 by a further aromatic ring as in 3 resulted in an even stronger inhibitor indicating that a large hydrophobic moiety properly protruding into the β-channel a of the enzyme can be beneficial for the binding.
14 Studies with each possible C-glucosyl oxadiazole isomer revealed that the constitution of the heterocycles was also an important factor and 5-β-Dglucopyranosyl-3-substituted-1,2,4-oxadiazoles 4 and 7 proved to be the best inhibitors of these series. 15, 16 Changing the oxadiazole to 1,2,4-triazole furnished inhibitors 5 and 8 exhibiting stronger binding most probably due to the H-bonding capacity of the triazoles, 17, 18 and imidazoles 6 and 9 were shown to be even better inhibitors. 19 Although no structural data have yet been available to rationalize this finding, one may speculate that the stronger inhibition of imidazoles can be a result of the smaller number of ring tautomers in comparison to the case of triazoles. Tautomeric forms have recently been shown to have a very important contribution to the determination of the binding strength of GP inhibitors. 20 The observation that the naphthyl substituted compounds 7-9 bind stronger to the enzyme than the phenyl substituted 4-6 corroborates the role of the large hydrophobic group. Based on the above considerations, we have designed 3-C-glucopyranosyl-1-substituted-1,2,4-triazol-5-ones as further candidates of potential GPIs in which the presence of the carbonyl group might result in decreasing the number of tautomers due to the stability of the NHCO moiety.
Results and discussion
Several methods were reported for the syntheses of various 1,2,4-triazol-5-ones, 21 e.g. starting with nitriles, 22, 23 imidates, 24 N 1 -acyl-semicarbazides, 25 N 1 -tosyl-amidrazones, 26 or aldehyde-semicarbazones. 27 C-Glycosyl-1,2,4-triazol-5-ones could not be located in the literature. The only related work found was that of Poonian and Nowoswiat 28 reporting the transformation of β-D-ribofuranosyl formimidate by (thio)semicarbazide to the corresponding C-β-D-ribofuranosyl-N 1 -(thio)carbamoyl formamidrazones. While the ring closure of the thiocarbamoyl derivative to a 1,2,4-triazol-5-thione could be achieved at elevated temperature, similar attempts to get the corresponding 1,2,4-triazol-5-one failed. 28 Since from earlier work we had in hand the O-perbenzoylated β-D-glucopyranosyl formimidate 14 (10, cleaved the protecting group and spontaneous ring closure gave the expected triazolone 27. To our surprise, this compound proved identical with that obtained by heating 25 in m-xylene; however, this unexpected outcome had a precedent in the literature. 34 Besides the chemical evidence of the route 26→27, spectroscopic verification for the structure of 27 was also sought for. To this end, a2D 1 H-1 H ROESY spectrum was recorded which showed the vicinity of the triazolone NH to H1 and H2 of the sugar moiety, thereby indicating the position of the aromatic residue ( Fig. 1 ; for the spectra see Supporting information). Deprotection of 27 under Zemplén conditions furnished test compound 28 in excellent yield.
In order to have a triazolone with a larger aromatic substituent, synthesis of the 2-naphthyl derivative was envisaged. Although a synthetic sequence analogous to 23→24→26→27 seemed straightforward, the unavailability of the necessary 2-naphthyl-hydrazine prevented the application of this route. Therefore, a copper catalyzed cross-coupling protocol for the N-arylation of amides was adapted. 35 The reaction of triazolone 19 with naphthalene-2-boronic acid in the presence of Cu(OAc)2 and Et3N gave low yield of 29 (Scheme 3). The structure of this product was considered to be analogous to that of 27 based on the coincidences of the chemical shifts both in the 1 H and 13 C NMR spectra of 27 and 29.I n addition, the structure was also corroborated by a 2D The new compounds were assayed against rabbit muscle glycogen phosphorylase b (RMGPb) as described previously 36 ( Table 2 ). The unsubstituted triazolone 20 and its 1-tosylated derivative 22 had no significant effect. In the case of 20, the inefficiency may be explained by the relatively small size of the aglycon which cannot interact in the β-channel of the enzyme. This resembles the case of the similarly non inhibitory 5-β-D-glucopyranosyl tetrazole. 12 For
22
, where the tosyl substituent can occupy the β-channel, the lack of efficiency may be attributed to the presence of the SO2 moiety. Such a tetrahedral linking element in the aglycon was shown to be detrimental to the binding in some types of glucose derived compounds. 8, 11, [38] [39] [40] The 1-aryl-substituted triazolones 28 and 30 had weak inhibitory effects whereby the 2-naphthyl derivative 30 showed stronger binding than the phenyl compound 28. This reflects the general trend regarding the size and orientation of aryl substituents that were observed in many cases (cf examples 4-6 vs 7-9 in Chart 1). On the other hand, the triazolone ring between the sugar Scheme 2. Reagents and conditions: a) (COCl)2, dry 1,2-dichloroethane, reflux; b) dry THF, 0°C to rt; c)d rym-xylene, reflux; d)C F 3COOH, dry CH2Cl2,r t ;e) cat. NaOMe in dry MeOH, rt. 147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175   176   177  178   179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199   200   201 and the aromatic part must have insufficient interactions with the amino acid side chains of RMGPb, resulting in weaker inhibition than many of other 5-membered C-glucosyl heterocycles studied so far.
In conclusion, synthetic methods have been elaborated to obtain hitherto unknown 3-β-D-glucopyranosyl-1-(un)substituted-1,2,4-triazol-5-ones. Enzyme kinetic tests with rabbit muscle glycogen phosphorylase b revealed 1-aryl-triazolones to be weak inhibitors, thereby contributing to structure-activity relationships of C-glucosyl heterocycles. For column chromatography, Kieselgel 60 (Merck, particle size 0.063-0.200 mm) was used. Toluene, m-xylene, CH2Cl2, CHCl3 were distilled from P4O10 and stored over 4 Å molecular sieves or sodium wires. MeOH was purified by distillation after refluxing for a couple of hours with magnesium turnings and iodine. THF was distilled from sodium benzophenone ketyl and stored over sodium wires. Anhydrous solvents: EtOH (Sigma-Aldrich), DMF (Sigma-Aldrich), 1,2-dichloroethane (Sigma-Aldrich) and pyridine (VWR) were purchased from the indicated companies. Ethyl C- (2,3,4,6- 30 (23) and PhNHNHBoc 41 were synthesized according to published procedures.
Experimental

General methods
tetra-O-benzoyl- β-D-glucopyranosyl)formimidate 14 (10), N 1 -tosyl-C-(2,3,4,6- tetra-O-benzoyl-β-D-glucopyranosyl)formamidrazone 17 (17), C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formamide
General procedure for removal of benzoyl protecting groups by the Zemplén protocol
To a solution of an O-perbenzoylated compound in anhydrous MeOH (5 mL/100 mg, a few drops of anhydrous CHCl3 were added in case of incomplete dissolution), a catalytic amount of a NaOMe solution (1 M in MeOH) was added and the mixture was left at rt. After completion of the reaction monitored by TLC (1:1 EtOAchexane and 7:3 CHCl3-MeOH), the mixture was neutralized with a cation exchange resin Amberlyst 15 (H + form), then the resin was filtered off and the solvent was removed. The crude product was purified by column chromatography.
14 (10, 1.00 g, 1.53 mmol) and ethyl carbazate (11 , 0.16 g 1.53 mmol) were stirred in anhydrous EtOH (20 mL) at reflux temperature, and the reaction was monitored by TLC (1:1 EtOAc-hexane). After completion of the reaction (5 h), the mixture was evaporated under diminished pressure, and the crude product was purified by column chromatography (1:1 EtOAc-hexane) to yield 0.60 g (55%) white solid. 
Ethyl
C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)formimidate
14 (10, 0.10 g, 0.15 mmol) and 2,4-dinitrophenylhydrazine (13, 61 mg, 0.31 mmol) were refluxed in anhydrous EtOH (3 mL), and the reaction was monitored by TLC (2:3 EtOAc-hexane). After total consumption of the imidate (1 d), the solvent was removed and the 
3-(3′,4′,6′-Tri-O-benzoyl-2′-deoxy-D-arabino-hex-1′-enopyranosyl)-1H-1,2,4-triazol-5(4H)-one (18)
The solution of amidrazone 14 (0.40 g, 0.56 mmol) in anhydrous m-xylene (8 mL) was heated at 140°C, and the reaction was monitored by TLC (4:1 EtOAc-hexane). After total consumption of the starting material (2 h) the solvent was removed, and the residue was purified by column chromatography (7:2 EtOAc-hexane) to yield 0. 
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (19)
The amidrazone 15 (2.0 g, 2.94 mmol) was refluxed in anhydrous DMF (50 mL), and the reaction was monitored by TLC (EtOAc). After disappearance of the starting material (2 h), the solvent was removed under reduced pressure, and the residue was purified by column chromatography (EtOAc) to yield 1. 
3-(β-D-Glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (20)
3-(2′,3′,4′,6′-Tetra-O-benzoyl-β-D-glucopyranosyl)-1-tosyl-1H-1,2,4-triazol-5(4H)-one (21)
To a solution of amidrazone 17 17 (0.20 g, 0.25 mmol) in anhydrous CHCl3 (3 mL) anhydrous pyridine (37 μL, 0.45 mmol, 1.8 equiv.) was added. The mixture was then cooled in an ice bath, and a solution of ethyl chloroformate (36 μl, 0.38 mmol, 1.5 ekv.) in anhydrous CHCl3 (3 mL) was added dropwise over 15 minutes. The mixture was then stirred at rt, and the reaction was monitored by TLC (2:3 EtOAchexane). After 1 week, the mixture was concentrated under diminished pressure, and the crude product was purified by column chromatography (1:2 EtOAc-hexane) to give 0.14 g (70%) white solid. 
3-(β-D-Glucopyranosyl)-1-tosyl-1H-1,2,4-triazol-5(4H)-one (22)
Prepared from compound 21 (0.20 g, 0.24 mmol) according to the general procedure (Section 3. 
3.11.
N 1 -Phenyl-N 4 -(2′,3′,4′,6′-tetra-O-benzoyl-β-D- glucopyranosylcarbonyl)semicarbazide (25)
To a solution of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)
formamide 30 (23, 2.5 g, 4.0 mmol) in anhydrous 1,2-dichloroethane (50 mL) oxalyl chloride (0.68 mL, 8.0 mmol) was added, and the mixture was refluxed for 1 d. The reaction mixture was then concentrated under diminished pressure, and traces of oxalyl chloride was removed by repeated co-evaporations with toluene. The remaining syrup was dissolved in anhydrous THF (50 mL), the solution was cooled to 0°C and phenylhydrazine (0.6 mL, 6.0 mmol) was added. Subsequently the reaction mixture was allowed to warm to rt and stirred for 1 d. The solvent was then removed under reduced pressure, and the residue was crystallized from diethyl ether to give (ppm): 168.0, 166.4, 165.7, 165.1 (2), 154.1 (C = O),  147.6, 133.6-133.2, 129.8-128.3, 121.0, 113.1 (Ar), 76.4, 76.2, 73.2 (26) To a solution of C-(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl) formamide 30 (23, 0.5 g, 0.80 mmol) in anhydrous 1,2-dichloroethane (12 mL) oxalyl chloride (136 μL, 0.16 mmol) was added, and the mixture was heated at reflux temperature for 1 d. The reaction mixture was then concentrated under diminished pressure, and traces of oxalyl chloride was removed by repeated co-evaporations with toluene. The remaining syrup was dissolved in anhydrous THF (10 mL), the solution was cooled to 0°C and PhNHNHBoc (0.25 g, 1.2 mmol) was added. Subsequently, the reaction mixture was allowed to warm to rt and stirred for 3 h. The solvent was then evaporated under reduced pressure and the residue was purified by column chromatography (1:2 EtOAc-hexane) to obtain the title compound 26 (0. (27) A: The solution of compound 25 (1.0 g, 1.32 mmol) in anhydrous m-xylene (40 mL) was heated at boiling temperature, and the reaction was monitored by TLC (1:1 EtOAc-hexane). After total consumption of the starting material (1 d), the solvent was removed, and the residue was purified by column chromatography (1:2 EtOAc-hexane) to give 0.36 g (37%) colourless syrup.
1-Phenyl-3-(2′,3′,4′,6′-tetra-O-benzoyl-β-D-glucopyranosyl)-1H-1,2,4-triazol-5(4H)-one
B:
To a solution of compound 26 (0.23 g, 0.27 mmol) in anhydrous CH2Cl2 (10 mL) trifluoroacetic acid (124 μL, 1.61 mmol) was added and the mixture was stirred at rt. After disappearance of the starting material (4 d) monitored by TLC (2:3 EtOAc-hexane), the solvent was removed under diminished pressure, and the residue was purified by column chromatography (1:2 EtOAchexane) to yield 0. 
3-(β-D-Glucopyranosyl)-1-phenyl-1H-1,2,4-triazol-5(4H)-one (28)
Prepared from compound 27 (0.23 g, 0.31 mmol) according to the general procedure (Section 3.2). 
1-(2-Naphthyl)-3-(2′,3′,4′,6′-tetra-O-benzoyl-β-Dglucopyranosyl)-1H-1,2,4-triazol-5(4H)-one (29)
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